Beyond market averages, investors looking for exceptional returns turn to stock picking. Skillful choices in individual stocks have the power to substantially increase your wealth.
In other words, the price has increased by $0.00 from its previous closing price. On the day, 2.27 million shares were traded. RNA stock price reached its highest trading level at $72.415 during the session, while it also had its lowest trading level at $72.255.
Ratios:
For a deeper understanding of Avidity Biosciences Inc’s stock, let’s take a closer look at its various ratios. For the most recent quarter (mrq), Quick Ratio is recorded 11.57 and its Current Ratio is at 11.57. In the meantime, Its Debt-to-Equity ratio is 0.03 whereas as Long-Term Debt/Eq ratio is at 0.02.
Upgrades & Downgrades
In the most recent recommendation for this company, Roth Capital on September 17, 2025, initiated with a Buy rating and assigned the stock a target price of $62.
On June 24, 2025, Bernstein started tracking the stock assigning a Outperform rating and target price of $50.Bernstein initiated its Outperform rating on June 24, 2025, with a $50 target price.
Insider Transactions:
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Oct 22 ’25 when Hughes Steven George sold 2,209 shares for $47.54 per share. The transaction valued at 105,015 led to the insider holds 38,867 shares of the business.
McCarthy Teresa sold 20,000 shares of RNA for $1,003,058 on Oct 15 ’25. The Chief Human Resources Officer now owns 97,130 shares after completing the transaction at $50.15 per share. On Oct 03 ’25, another insider, Mosbrooker Eric, who serves as the Chief Commercial Officer of the company, sold 6,562 shares for $45.38 each. As a result, the insider received 297,771 and left with 55,000 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, RNA now has a Market Capitalization of 10904403968 and an Enterprise Value of 9078533120. For the stock, the TTM Price-to-Sale (P/S) ratio is 522.75 while its Price-to-Book (P/B) ratio in mrq is 5.63. Its current Enterprise Value per Revenue stands at 435.046 whereas that against EBITDA is -14.906.
Stock Price History:
The Beta on a monthly basis for RNA is 0.93, which has changed by 1.4565513 over the last 52 weeks, in comparison to a change of 0.1877265 over the same period for the S&P500. Over the past 52 weeks, RNA has reached a high of $72.61, while it has fallen to a 52-week low of $21.51. The 50-Day Moving Average of the stock is 1.58%, while the 200-Day Moving Average is calculated to be 59.26%.
Shares Statistics:
For the past three months, RNA has traded an average of 4.79M shares per day and 1678600 over the past ten days. A total of 146.77M shares are outstanding, with a floating share count of 138.08M. Insiders hold about 8.40% of the company’s shares, while institutions hold 95.52% stake in the company. Shares short for RNA as of 1765756800 were 9740063 with a Short Ratio of 2.03, compared to 1763078400 on 10321719. Therefore, it implies a Short% of Shares Outstanding of 9740063 and a Short% of Float of 6.510000000000001.
Earnings Estimates
The dynamic stock of Avidity Biosciences Inc (RNA) is currently attracting attention from 11.0 analysts actively involved in rating its market status.The consensus estimate for the next quarter is -$1.28, with high estimates of -$0.98 and low estimates of -$1.59.
Analysts are recommending an EPS of between -$3.62 and -$5.16 for the fiscal current year, implying an average EPS of -$4.49. EPS for the following year is -$4.89, with 14.0 analysts recommending between -$3.24 and -$6.53.
Revenue Estimates
A total of 13 analysts believe the company’s revenue will be $1.98M this quarter.It ranges from a high estimate of $12.5M to a low estimate of -$6.5M. As of . The current estimate, Avidity Biosciences Inc’s year-ago sales were $2.97M
A total of 13 analysts have provided revenue estimates for RNA’s current fiscal year. The highest revenue estimate was $30.4M, while the lowest revenue estimate was $5.4M, resulting in an average revenue estimate of $18.36M. In the same quarter a year ago, actual revenue was $10.9M
